---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-005203"
form_type: "8-K"
ticker: "BCPC"
cik: "0000009326"
company_name: "BALCHEM CORP"
filed_at: "2024-02-16T23:59:59+00:00"
generated_at: "2026-06-06T00:35:52.126172+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Balchem Q4 adj. EBITDA up 5.4% to $55.4M; free cash flow $56M, record Human Nutrition sales

## Summary
- Q4 GAAP EPS $0.82 vs $0.66 prior year; adjusted EPS $0.95 vs $0.94.
- Full year adjusted EBITDA $230.9M (+7.1%); record free cash flow $151.1M.
- Human Nutrition & Health Q4 sales $138M (+5.8%) record; earnings from ops up 43.8%.
- Dividend increased double-digit; $25.4M returned to shareholders in 2023.
- CEO expects both top and bottom line growth for full year 2024.

## SEC filing metadata
- accession: 0001628280-24-005203
- form_type: 8-K
- ticker: BCPC
- cik: 0000009326
- company_name: BALCHEM CORP
- filed_at: 2024-02-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/9326/000162828024005203/0001628280-24-005203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/9326/000162828024005203/bcpc-20240216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-005203
- JSON: https://secwatch.observer/filing/0001628280-24-005203.json
- Plain text: https://secwatch.observer/filing/0001628280-24-005203.txt

## Key facts
- Earnings Releases
  BALCHEM CORP reported Q4 2023 (three months ended December 31, 2023) results: revenue $228.7 million, net income $26.6 million, EPS $0.82.
  - Period: Q4 2023 (three months ended December 31, 2023)
  - Revenue: $228.7 million
  - Net income: $26.6 million
  - EPS: $0.82
  - Result: reported results
  source text: The Company reported quarterly net sales of $228.7 million, quarterly net earnings of $26.6 million, adjusted EBITDA (a) of $55.4 million, and free cash flow (a) of $56.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/9326/000162828024005203/0001628280-24-005203-index.htm
- Earnings Releases
  BALCHEM CORP reported FY 2023 (year ended December 31, 2023) results: revenue $922.4 million, net income $108.5 million, EPS $3.35.
  - Period: FY 2023 (year ended December 31, 2023)
  - Revenue: $922.4 million
  - Net income: $108.5 million
  - EPS: $3.35
  - Result: preliminary results
  source text: Full Year 2023 Financial Highlights: • GAAP net earnings were $108.5 million, an increase of 3.0% from the prior year. These net earnings resulted in GAAP earnings per share of $3.35 compared to $3.25 in the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/9326/000162828024005203/0001628280-24-005203-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.